MIAMI, Jan. 24, 2008 (PRIME NEWSWIRE) -- Galea Life Sciences, Inc. (Pink Sheets:GLSN) announced today that BioSource Therapeutics, Inc. (BST), its wholly-owned subsidiary, has named Dr. Terence M. Dolak, Ph.D. as the Chief Scientific Advisor. BST is the maker of Nutraplete(tm) Therapeutic Drink Mix, the first dietary supplement product designed specifically for people living with HIV/AIDS.
"This is an exciting opportunity to work with BioSource Therapeutics, Inc.," said Dr. Dolak. "Nutraplete is a significant step in meeting the special health needs of people afflicted with HIV/AIDS and to help improve the quality of their lives. I look forward to working with BST's remarkable team of business professionals and clinicians who are working to make a positive change in the lives of millions of people."
Dr. Dolak has devoted over 25 years designing and developing new drugs and healthcare products and holds over 110 patents. He founded SDR Pharmaceuticals, an oncology company, and Seraph Chem, a contract chemistry company servicing the pharmaceutical industry. Dr. Dolak has led the discovery and development of a wide range of pharmaceutical, health care and consumer products resulting in over 1500 commercial products. He has held executive positions with Bristol-Meyers, Wyeth, Bausch & Lomb, Galderma and Revlon. He has also published over 45 scientific papers and made numerous business and technical presentations. Dr. Dolak serves on the Board of Directors and Scientific Advisory Boards of several biotech companies.
"We are privileged to have someone of Dr. Dolak's caliber bringing his wealth of experience and scientific knowledge to BioSource Therapeutics, Inc.," said David Miller, President & CEO. "His distinguished career highlights a special focus on the creation and development of products that address human health and the quality of life. Dr. Dolak also brings an in-depth knowledge of medicinal chemistry and drug design that will enable us to expand the breadth of our technology and product offerings."
About Nutraplete
Nutraplete is the first therapeutic dietary supplement designed specifically for people living with HIV/AIDS. It is a multi-nutritional supplement, designed to address AIDS Wasting Syndrome. It works in conjunction with antiviral therapies and assists patients in the adherence and tolerance of treatments. Nutraplete is a "functional food" that encourages the restoration of lean body mass, can inhibit pro-oxidative stress, and improves immune function. Nutraplete is available by prescription, and has started the application process for inclusion with Medicaid and AIDS Drugs Assistance Program (ADAP) formularies. Nutraplete is distributed nationally by Allion Healthcare, Inc. (Nasdaq:ALLI) under its MOMS Pharmacy trade name. www.momspharmacy.com.
For more information: www.nutraplete.com
About Galea Life Sciences, Inc.
Galea Life Sciences, Inc. (Pink Sheets:GLSN) is currently a non-reporting over-the-counter publicly traded company. GLSN identifies and acquires new and innovative nutraceutical product and dietary supplement companies with outstanding growth potential. GLSN's focus is in the emerging scientific field of advanced nutritional supplements designed to support traditional medical treatments and therapies. BioSource Therapeutics, Inc. (BST), a GLSN subsidiary, is an entrepreneurial life sciences company. BST specializes in the formulation, manufacturing, marketing and distribution of innovative dietary supplements that benefit people undergoing medical treatments and therapies.
The Galea Life Sciences logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4489
Certain statements in this release constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast," "project," "intend," "expect" "should," "would," and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (finance or operating) or achievements to differ from future results, performance (financing and operating) or achievements expressed or implied by such forward-looking statements.
Statements herein express management's beliefs and expectations regarding future performance and are forward-looking and involve risks and uncertainties, including, but not limited to, the ability to negotiate outstanding prior debts of acquired companies; properly identify acquisition partners; adequately perform due diligence; manage and integrate acquired businesses; react to quarterly fluctuations in results; raise working capital and secure other financing; respond to competition and rapidly changing technology; deal with market and stock price fluctuations; and other risks.